<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: Proteinuric diabetic patients with reduced glomerular filtration rate (GFR) are at high risk of renal and <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> progression and treatment-related adverse events </plain></SENT>
<SENT sid="1" pm="."><plain>This post hoc analysis assessed the efficacy and safety of <z:chebi fb="0" ids="601027">aliskiren</z:chebi> added to the maximal recommended dose of <z:chebi fb="0" ids="6541">losartan</z:chebi> according to baseline estimated GFR (eGFR) (stage 1-3 <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C0022658" disease_type="Disease or Syndrome" abbrv="">kidney disease</z:e> [CKD]) </plain></SENT>
<SENT sid="2" pm="."><plain>RESEARCH DESIGN AND METHODS: In the <z:chebi fb="0" ids="601027">Aliskiren</z:chebi> in the Evaluation of <z:hpo ids='HP_0000093'>Proteinuria</z:hpo> in <z:mp ids='MP_0002055'>Diabetes</z:mp> (AVOID) study, 599 hypertensive patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and <z:hpo ids='HP_0000112'>nephropathy</z:hpo> received 6 months of <z:chebi fb="0" ids="601027">aliskiren</z:chebi> (150 mg daily titrated to 300 mg daily after 3 months) or placebo added to 100 mg <z:chebi fb="0" ids="6541">losartan</z:chebi> and optimal <z:chebi fb="0" ids="35674">antihypertensive</z:chebi> therapy </plain></SENT>
<SENT sid="3" pm="."><plain>Exclusion criteria included eGFR&lt;30 ml/min per 1.73 m2 and serum <z:chebi fb="120" ids="26216">potassium</z:chebi>&gt;5.1 mmol/l </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Baseline characteristics were similar between treatment groups in <z:hpo ids='HP_0000001'>all</z:hpo> CKD stages </plain></SENT>
<SENT sid="5" pm="."><plain>The antiproteinuric effects of <z:chebi fb="0" ids="601027">aliskiren</z:chebi> were consistent across CKD stages (19, 22, and 18% reduction) </plain></SENT>
<SENT sid="6" pm="."><plain>In the stage 3 CKD group, baseline serum <z:chebi fb="0" ids="16737">creatinine</z:chebi> levels were equal, but <z:hpo ids='HP_0000082'>renal dysfunction</z:hpo>, prespecified as a postrandomization serum <z:chebi fb="0" ids="16737">creatinine</z:chebi> elevation&gt;176.8 Î¼mol/l (2.0 mg/dl) occurred more frequently in the placebo group (29.2 vs. 13.6%, P=0.032) </plain></SENT>
<SENT sid="7" pm="."><plain>Serum <z:chebi fb="120" ids="26216">potassium</z:chebi> elevations&gt;5.5 mmol/l (based on a single measurement) were more frequent with <z:chebi fb="0" ids="601027">aliskiren</z:chebi> (22.5 vs. 13.6%) in stage 3 CKD </plain></SENT>
<SENT sid="8" pm="."><plain>Adverse event rates were similar between treatments, irrespective of CKD stage </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: <z:chebi fb="0" ids="601027">Aliskiren</z:chebi> added to <z:chebi fb="0" ids="6541">losartan</z:chebi> reduced <z:mp ids='MP_0002871'>albuminuria</z:mp> and <z:hpo ids='HP_0000082'>renal dysfunction</z:hpo> and was well tolerated, except for <z:hpo ids='HP_0002153'>hyperkalemia</z:hpo> (stage 3), independent of baseline CKD stage in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, <z:hpo ids='HP_0000822'>hypertension</z:hpo>, and <z:hpo ids='HP_0000112'>nephropathy</z:hpo> </plain></SENT>
</text></document>